Genetic variation in humans has been catalogued as, for example, by the International HapMap Project. A haplotype is an assemblage of some or all of the genetic variation on a chromosome. It is important to know whether two or more genetic variants (either mutations or non-deleterious polymorphisms) are present on the same or different homologous chromosomes, i.e., whether they are adjacent to one another or on opposite chromosomes. This is because they may interact depending on whether they are in cis or trans. Examples of this type of genetic interactions include: asthma, where certain drugs work better or worse depending upon the interplay of several genetic differences in the ADRB2 gene; and a common form of male sterility which is due to the interaction of two mutations in the CFTR gene. In these and similar disorders where medical treatment depends upon an individual's genetic status, haplotyping tests to obtain this information are either dependent upon population-based assumptions that may not hold for an individual, or are extremely difficult and expensive. Thus, there is need for a method to determine long-range haplotypes (those separated by thousands of nucleotides) directly. This project will expand upon preliminary studies which show that a specialized form of molecular testing can meet many of these medical needs. The overall goal of the this proposal is to develop and refine a method for identifying haplotypes spanning many kilobases that is rapid, simple, inexpensive, requires only small amounts of genomic DNA, and is easily scalable for large population studies. The prototype assay is termed LLR.
The specific aims for this program are to: 1) develop an assay to haplotype the beta-2-adrenergic receptor (ADRB2) gene using LLR; and 2) develop an assay to haplotype the cystic fibrosis transmembrane conductance regulator (CFTR) gene for deltaF508 and 5T/7T/9T mutations using LLR. This novel, technology-based project has the potential to produce major advances in clinical genetics and pharmacogenomics by providing a tool for correctly characterizing human genetic variation. A large part of health is dependent on genetics. This project will develop a new genetic test to predict who will inherit or who has certain diseases like male sterility. The new test will also be useful in determining the effectiveness of drug treatment, for example, in asthma patients because there is a genetic component to the drug response. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Human Genome Research Institute (NHGRI)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21HG004315-02
Application #
7489000
Study Section
Genomics, Computational Biology and Technology Study Section (GCAT)
Program Officer
Ozenberger, Bradley
Project Start
2007-09-01
Project End
2010-06-30
Budget Start
2008-07-01
Budget End
2010-06-30
Support Year
2
Fiscal Year
2008
Total Cost
$246,000
Indirect Cost
Name
Johns Hopkins University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Lin, Ming-Tseh; Tseng, Li-Hui; Dudley, Jonathan C et al. (2015) A Novel Tandem Duplication Assay to Detect Minimal Residual Disease in FLT3/ITD AML. Mol Diagn Ther 19:409-17
Grunwald, Michael R; Tseng, Li-Hui; Lin, Ming-Tseh et al. (2014) Improved FLT3 internal tandem duplication PCR assay predicts outcome after allogeneic transplant for acute myeloid leukemia. Biol Blood Marrow Transplant 20:1989-95
Lin, Ming-Tseh; Mosier, Stacy L; Thiess, Michele et al. (2014) Clinical validation of KRAS, BRAF, and EGFR mutation detection using next-generation sequencing. Am J Clin Pathol 141:856-66
Lin, Ming-Tseh; Tseng, Li-Hui; Beierl, Katie et al. (2013) Tandem duplication PCR: an ultrasensitive assay for the detection of internal tandem duplications of the FLT3 gene. Diagn Mol Pathol 22:149-55
Lin, Ming-Tseh; Tseng, Li-Hui; Beierl, Katie et al. (2011) Analysis of hematopoietic stem cell transplant engraftment: use of loss or gain of microsatellite alleles to identify residual hematopoietic malignancy. Diagn Mol Pathol 20:194-202